{"id":674210,"date":"2023-10-27T19:34:02","date_gmt":"2023-10-27T19:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=674210"},"modified":"2023-10-27T19:34:02","modified_gmt":"2023-10-27T19:34:02","slug":"respiratory-syncytial-virus-clinical-trials-growth-and-key-companies-companiesglaxosmithkline-medimmune-reviral-pfizer-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/respiratory-syncytial-virus-clinical-trials-growth-and-key-companies-companiesglaxosmithkline-medimmune-reviral-pfizer-and-many-others_674210.html","title":{"rendered":"Respiratory Syncytial Virus  Clinical Trials, Growth, and Key Companies | Companies &#8211; GlaxoSmithKline, MedImmune, ReViral, Pfizer, and many others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Respiratory Syncytial Virus  Clinical Trials, Growth, and Key Companies | Companies - GlaxoSmithKline, MedImmune, ReViral, Pfizer, and many others \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Respiratory Syncytial Virus  Clinical Trials, Growth, and Key Companies | Companies - GlaxoSmithKline, MedImmune, ReViral, Pfizer, and many others \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas Nevada United States), DelveInsight\u2019s, \u201cRespiratory Syncytial Virus (RSV) &#8211; Pipeline Insight, 2023,\u201d report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">(Las Vegas Nevada United States), DelveInsight&rsquo;s, <strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Respiratory Syncytial Virus (RSV) &#8211; Pipeline Insight, 2023<\/a><\/strong>,&rdquo; report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Respiratory Syncytial Virus Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Respiratory Syncytial Virus&nbsp; companies developing novel drug candidates to improve the Food Allergy&nbsp; treatment landscape include GlaxoSmithKline, MedImmune, ReViral, Pfizer, and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Respiratory Syncytial Virus pipeline therapies in various stages of development include MEDI-8897, Sisunatovi, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Respiratory Syncytial Virus Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/4b6273e0fdd610eb7bfd560ca626d22b.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Respiratory Syncytial Virus Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&nbsp;GSK3844766A: GlaxoSmithKline<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK&rsquo;s proprietary AS01 adjuvant, which is also used in GSK&rsquo;s shingles vaccine. Currently, it is in phase III of the development stage for the treatment of Respiratory Syncytial Virus (RSV).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Discover more about the emerging Food Allergy&nbsp; drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Respiratory Syncytial Virus&nbsp; Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Respiratory Syncytial Virus Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;GlaxoSmithKline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;MedImmune<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;ReViral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Sanofi<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BioComo<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Respiratory Syncytial Virus Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight&rsquo;s Report covers around 10+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Product Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Drugs have been categorized under various product types like Mono, Combination, and Mono\/Combination.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Respiratory Syncytial Virus Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Respiratory Syncytial Virus &nbsp;Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer,&nbsp; Sanofi, BioComo and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Respiratory Syncytial Virus Pipeline Therapies : GSK3844766A, Nirsevimab, Sisunatovir and many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Find out more about the Food Allergy&nbsp; treatment options in development @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Respiratory Syncytial Virus Clinical Trials<\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Table of Contents<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Respiratory Syncytial Virus&nbsp; Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Respiratory Syncytial Virus&nbsp; Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Respiratory Syncytial Virus Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Respiratory Syncytial Virus Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Respiratory Syncytial Virus &nbsp;&nbsp;Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Respiratory Syncytial Virus Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Respiratory Syncytial Virus Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Respiratory Syncytial Virus &nbsp;Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Respiratory Syncytial Virus&nbsp; Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Respiratory Syncytial Virus Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Respiratory Syncytial Virus Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12 Respiratory Syncytial Virus&nbsp; Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Respiratory Syncytial Virus&nbsp; Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Respiratory Syncytial Virus&nbsp; Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=respiratory-syncytial-virus-clinical-trials-growth-and-key-companies-companiesglaxosmithkline-medimmune-reviral-pfizer-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=respiratory-syncytial-virus-clinical-trials-growth-and-key-companies-companiesglaxosmithkline-medimmune-reviral-pfizer-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP (Las Vegas Nevada United States), DelveInsight\u2019s, \u201cRespiratory Syncytial Virus (RSV) &#8211; Pipeline Insight, 2023,\u201d report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. (Las Vegas Nevada United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/respiratory-syncytial-virus-clinical-trials-growth-and-key-companies-companiesglaxosmithkline-medimmune-reviral-pfizer-and-many-others_674210.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-674210","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/674210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=674210"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/674210\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=674210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=674210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=674210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}